Without Community, Research is Not Possible: Community Engagement in TB Research
When TB Alliance was formed, there had been no late-stage tuberculosis (TB) research trials conducted to modern standards. In addition […]
Uncategorized
At United Nations High Level Meeting, World Leaders Commit to Ending TB
Unfortunately, the recent history of the tuberculosis (TB) pandemic has in large part been defined by neglect—inadequate funding for research
Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development
NEW YORK (July 15, 2021)—To advance anti-tuberculosis (TB) science and enable the progression of new, safe, and affordable treatment solutions
New Trial Results Show Effectiveness of BPaL Regimen for Highly Drug-Resistant TB Can Be Maintained with Reduced Dosing of Linezolid
TB Alliance’s ZeNix trial in South Africa and Eastern Europe sought to optimize the 6-month treatment regimen with reduced exposure
TB Alliance Welcomes Dr. Suvanand Sahu to the Access Advisory Committee
He will bring more than 20 years of global and country level experience in TB and a people-centered approach to
TB Alliance Congratulates Dr. Dan Everitt on Career Transition
After more than 40 years working in medicine, Dan Everitt, MD, is moving on from his role as Vice President
The First Clinical Trial of Multiple New TB Drugs in Combination
TB Alliance has shifted the TB treatment research paradigm from a focus on developing individual drugs to one of developing
Combating the TB Pandemic Amid a New Threat
As TB Alliance acknowledges its 20th year, we remain committed to advancing new cures and meeting the aspirations of those
A Persistent Shortfall in TB Research and Development Funding
NEW YORK (April 15, 2021)—The 2020 G-Finder Report, released today, shows that low funding levels are putting life-saving science—and especially
Astellas and TB Alliance Enter into a New Collaborative Research Agreement to Identify Lead Compounds for the Treatment of Tuberculosis
TOKYO and NEW YORK (March 31, 2021)—Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) and